Lincoln Pharmaceuticals Limited — Others, 14-02-2025: Copy of Newspaper Publication

Lincoln Pharmaceuticals has announced a board meeting to review the unaudited financial results for the quarter and nine months ending December 31, 2024. The company reported a total income from operations of ₹11.88 crore, with a net loss after tax of ₹57.53 crore for the period. Additionally, the comprehensive income for the period reflects the same net loss figure. The equity share capital remains steady at ₹402.86 crore. This announcement may lead to a cautious investor sentiment due to the ongoing losses, albeit with potential for recovery as the company continues to operate in a challenging environment.